BTX - Why Brooklyn ImmunoTherapeutics Stock Crushed It in April
Brooklyn ImmunoTherapeutics (NYSEMKT: BTX) , a relative newcomer to the world of publicly traded biotech stocks, saw its shares rip higher in April by a stunning 1,230%, according to data provided by S&P Global Market Intelligence . The stock took flight last month for two related reasons:
Image source: Getty Images.
Perhaps the most compelling aspect of this story is the fact that Brooklyn may not have a product approved by the Food and Drug Administration on the market until 2026. The company's lead product candidate is the immunotherapy IRX-2 , which won't wrap up late-stage testing for head and neck cancer until 2025.
For further details see:
Why Brooklyn ImmunoTherapeutics Stock Crushed It in April